Erius syrup reduces allergy symptoms – itching, sneezing, runny nose, and irritation of the skin and eyes.
1 ml of syrup contains:
Active substance: Desloratadine 0.5 mg
Excipients: propylene glycol, liquid sorbitol, citric acid, disodium citrate dihydrate, disodium edetate, sodium benzoate, sucrose, flavor (#15864), yellow dye #6 (E110), purified water
Pharmacodynamics: Desloratadine is a long-acting, non-sedating antihistamine with selective peripheral H1 receptor antagonism. After oral administration, desloratadine selectively blocks peripheral H1-histamine receptors without crossing the blood-brain barrier.
Safety of Erius syrup has been demonstrated in three studies involving children. Plasma concentrations of desloratadine in children and adults were comparable at recommended doses, allowing adult data to be extrapolated to children.
Desloratadine does not induce drowsiness at recommended doses (5 mg/day for adults and adolescents) compared to placebo. Clinical studies show it does not enhance alcohol-related effects such as impaired psychomotor function.
Pharmacokinetics: Desloratadine is measurable in plasma within 30 minutes of administration. Maximum plasma concentration is reached approximately 3 hours post-dose. The elimination half-life is about 27 hours. Protein binding is moderate (83–87%). Erius tablets and syrup are bioequivalent.
Relief of allergic rhinitis symptoms (nasal inflammation due to allergies, e.g., hay fever or dust mite allergy) in adults, adolescents, and children aged 1 year and older. Symptoms include sneezing, itching, runny nose, nasal congestion, eye itching/redness, and tearing.
Relief of urticaria symptoms (skin reactions due to allergies), including itching and rash.
Erius provides symptom relief throughout the day, helping maintain normal daily activities and restoring sleep.
Taken orally, with or without food.
Children:
1–5 years: 2.5 ml syrup (1.25 mg desloratadine) once daily
6–11 years: 5 ml syrup (2.5 mg desloratadine) once daily
Adults and adolescents (≥12 years):
10 ml syrup (5 mg desloratadine) once daily
Allergic rhinitis therapy:
Intermittent: stop when symptoms resolve and resume upon symptom recurrence
Persistent: continue treatment throughout allergen exposure
Missed dose: take as soon as possible; do not double the dose.
Special populations:
Safety and efficacy not established in children under 1 year, elderly patients, or patients with severe renal or hepatic impairment.
Erius may cause side effects, though not everyone experiences them. Rare severe allergic reactions may occur (difficulty breathing, angioedema, hives).
Children (under 2 years, common): diarrhea, fever, insomnia
Adults (common): fatigue, dry mouth, headache
Post-marketing (very rare in adults, ≤1/10,000): severe allergic reactions, rash, palpitations, abdominal pain, nausea, vomiting, gastrointestinal disorders, dizziness, drowsiness, sleep disturbances, muscle pain, hallucinations, convulsions, liver inflammation, abnormal liver function tests
Hypersensitivity to any component of the product or loratadine.
Use with caution in patients with a history of seizures.
Syrup contains sucrose and sorbitol; not recommended for patients with hereditary fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency.
Contains 23 mg sodium per 10 ml; negligible sodium content.
Consult a doctor if you have kidney disease before using Erius.
Accidental overdose is unlikely to cause serious adverse effects. Symptoms may be similar to those observed at therapeutic doses. Consult a doctor immediately if overdose occurs.
Safety in pregnancy not established; not recommended.
Desloratadine passes into breast milk; breastfeeding women should avoid Erius.
Erius at recommended doses does not affect the ability to drive or operate machinery. Avoid tasks requiring alertness until individual response is known.
Store at temperatures not exceeding 30°C, out of reach of children.
